Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $278.59

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-four analysts that are covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $278.59.

Several research firms have issued reports on ALNY. Evercore ISI upped their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, June 25th. JPMorgan Chase & Co. boosted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a "neutral" rating in a research note on Monday, August 26th. Cantor Fitzgerald boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the company a "neutral" rating in a research note on Monday, July 22nd. Leerink Partners boosted their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a "market perform" rating in a report on Tuesday, June 25th. Finally, Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a "buy" rating in a report on Friday, August 2nd.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the company's stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares in the company, valued at $18,602,548.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Dennis A. Ausiello sold 20,250 shares of the company's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares of the company's stock, valued at $35,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 8,301 shares of the company's stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares of the company's stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Insiders sold 103,148 shares of company stock worth $25,658,824 over the last ninety days. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Souders Financial Advisors raised its position in shares of Alnylam Pharmaceuticals by 1.0% during the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company's stock valued at $853,000 after buying an additional 36 shares during the last quarter. V Square Quantitative Management LLC raised its position in shares of Alnylam Pharmaceuticals by 21.9% during the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company's stock valued at $81,000 after buying an additional 60 shares during the last quarter. Commerce Bank raised its position in shares of Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company's stock valued at $896,000 after buying an additional 77 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Alnylam Pharmaceuticals by 7.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company's stock worth $262,000 after purchasing an additional 89 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 54.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 8.5 %

ALNY traded down $24.32 during trading on Monday, reaching $262.69. The stock had a trading volume of 3,762,500 shares, compared to its average volume of 901,793. The firm has a market capitalization of $33.72 billion, a price-to-earnings ratio of -98.02 and a beta of 0.37. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $287.55. The stock has a 50 day moving average of $255.96 and a two-hundred day moving average of $187.86.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The business's revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter last year, the company earned ($2.21) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals will post -2.82 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.